Text and Data Mining valid from 2018-05-01
First Online: 7 May 2018
Compliance with Ethical Standards
: No sources of funding were used to conduct this study or prepare this manuscript.
: Three of the six authors are principal investigators or subinvestigators on several Janssen-supported studies of esketamine for depression. PM is supported by Clinica Universidad de Navarra and has received research grants from the Ministry of Education (Spain), the Government of Navarra (Spain), the Spanish Foundation of Psychiatry and Mental Health and Astrazeneca. Without any relevance to this work, PM declares that he is a clinical consultant for MedAvante-ProPhase and has received speaker honoraria from Scienta, AB-Biotics and Janssen. PM is the principal investigator at Clinica Universidad de Navarra of several studies supported by Janssen about the efficacy and safety of esketamine. JARQ is the principal investigator for Hospital Universitari Vall d’Hebron in several studies about the efficacy and safety of esketamine supported by Janssen-Cilag. ECS is cooperating as subinvestigator at Hospital Universitari Vall d’Hebron in several studies about the efficacy and safety of esketamine for the treatment of depression supported by Janssen-Cilag. LGR has been speaker and advisory board member for Janssen, Rovi, Servier, Lundbeck, Otsuka, Pfizer and Exeltis. RMS and JJM have no conflicts of interest.